Palvella Therapeutics (PVLA) Debt Ratio (2013 - 2025)
Palvella Therapeutics (PVLA) reported Debt Ratio of 0.04 for Q4 2025, up 64.47% year-over-year from 0.02 in Q4 2024, and up 11.37% on a QoQ basis from 0.03 in Q3 2025.
Palvella Therapeutics (PVLA) has 4 years of Debt Ratio data on file, last reported at 0.04 in Q4 2025.
- Quarterly Debt Ratio rose 64.47% year-over-year to 0.04 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.04 (up 64.47% YoY) and the FY2025 annual result came in at 0.04, up 64.47% from the prior year.
- Debt Ratio rose to 0.04 in Q4 2025 per PVLA's latest filing, from 0.03 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.04 in Q4 2025 and bottomed at 0.02 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.18 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 1.41 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.05 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.04 |
| Sep 30, 2025 | 0.03 |
| Jun 30, 2025 | 0.03 |
| Mar 31, 2025 | 0.02 |
| Dec 31, 2024 | 0.02 |
| Dec 31, 2014 | 0.06 |
| Sep 30, 2014 | 17.95 |
| Jun 30, 2014 | 0.09 |
| Mar 31, 2014 | 12.62 |
| Dec 31, 2013 | 0.23 |
| Jun 30, 2013 | 0.09 |